Integrase (IN) mediates the covalent insertion of the retroviral genome into its host chromosomal DNA. This enzymatic activity can be reconstituted in vitro with short DNA oligonucleotides, which mimic a single viral DNA end, and purified IN. Herein we report a highly efficient and sensitive high-throughput screen, HIV Integrase Target SRI Assay (HITS™), for HIV-1 IN activity using 5′ biotin-labeled DNA (5′ BIO donor) and 3′ digoxygenin-labeled DNA (3′ DIG target). Following 3′ processing of the 5′ BIO donor, strand transfer proceeds with integration of the 5′ BIO donor into the 3′ DIG target. Products were captured on a streptavidin-coated microplate and the amount of DIG retained in the well was measured. The end point values, measured as absorbance, ranged from 0.9 to 1.5 for IN-mediated reactions as compared with background readings of 0.05 to 0.12. The Z factor for the assay ranged from 0.7 to 0.85. The assay was used to screen drugs in a high-throughput format, and furthermore, we adapted the assay to study mechanistic questions regarding the integration process. For example, using variations of the assay format, we showed high preference of E strand of the long terminal repeat (LTR) viral DNA as a target strand compared with its complementary A strand. The E strand is the strand processed by IN. Furthermore, we explored the reported inhibitory effect of reverse transcriptase on integration. (Journal of Biomolecular Screening 2005:606-614) 
INTRODUCTION
I NTEGRATION IS CHARACTERISTIC and fundamental to the retrovirus life cycle because it is necessary for stable maintenance of the retroviral genome and high-level expression of viral genes. [1] [2] [3] [4] [5] The 2 basic viral components required for integration include specific DNA sequences at the U5 and U3 end of each of the long terminal repeat regions (LTR) of the viral genome and integrase (IN). However, integration of the retroviral genome into the host is a complex process that requires a number of viral and cellular proteins to protect and transport the viral complementary DNA from the cytoplasm into the nucleus. [6] [7] [8] IN possesses 2 unique and biologically relevant enzymatic activities: 1) a 3′ processing activity that removes the 3′ GT dinucleotide from the LTR end, and 2) a strand transfer activity that coordinates a nucleophilic attack of the free 3′ hydroxyl group of the processed LTR end on a phosphodiester bond in the target DNA. 9 Each of these activities has been demonstrated in vitro by making use of short duplex oligonucleotides (18-35 bp) mimicking the U5 or U3 ends and recombinant IN. 10, 11 Given IN's critical role in the virus life cycle, IN is a strategic target for antiviral drug therapy. [12] [13] [14] During the past decade, in vitro assays have been adapted to a microplate format and used to monitor the enzyme activity of the human immunodeficiency virus type-1 (HIV-1) IN alone and in the presence of inhibitors. 11, 15, 16 Some of these assays measure 3′ processing and strand transfer activity together, whereas others measure strand transfer activity alone. Assays formatted in this manner offer a viable approach to the screening of antiviral compounds. Furthermore, the development of convenient, high-throughput methods for enzymatic activity is critical to define quantifiable structure-activity relationships of antiviral compounds. Herein, we describe a new approach to HIV-1 IN activity using high-throughput screening (HTS) technology that is suitable for rapid, efficient screening of drug candidates and molecular probes for mechanistic studies. In addition to HTS, 2 notable improvements were made in the development of this assay. First, the entire assay was conducted in the context of a 96-well microplate so that the entire procedure was completed in the same plate, which is essential for efficient HTS. Second, the assay was optimized to reduce the nonspecific binding of IN and its substrates bound in situ as well as nonspecific hybridization of the target strand forming complexes. In addition to these developments, we demonstrate how this assay can be adapted to study the reaction mechanism in a high-throughput manner.
MATERIALS AND METHODS

Materials
Culture media components and isopropyl-thio-galactoside (IPTG) were purchased from Fisher Scientific (Pittsburgh, PA). Electrophoresis and protein assays reagents were obtained through Bio-Rad (Hercules, CA). The plasmid pINSD.HIS containing HIV-1 IN was obtained from the AIDS Research and Reference Reagent Program. The streptavidin-coated microplates, peroxidase coupled anti-digoxygenin (DIG) antibody and 2,2´-Azino-bis (3-ethylbenziazoline-6-sulfonic acid) (ABTS) substrates were purchased from Roche Applied Sciences (Indianapolis, IN) and the biotin (BIO)-labeled and DIG-labeled DNA oligomers were purchased from Integrated DNA Technologies Inc (Coralville, IA).
Protein purification
HIV-1 IN was expressed in Escherichia coli BL-21 (DE3) as a hexahistidine-tagged fusion protein and purified from the soluble fraction as described previously 17 with the following modifications. Cells were grown to mid-logarithmic phase in Luria-Bertaini medium and induced for 2 h with 1 mM IPTG. Cells were centrifuged, resuspended in 10 ml 1× binding buffer (1 M NaCl, 20 mM Tris, pH 7.9, 5 mM imidazole), lysed with lysozyme (0.2 mg/ml) and dounced for 1 h. Cells were sonicated for 1 min on ice for 5 times with a 1-min break followed by centrifugation for 30 min at 30,000g, and the supernate was collected. The pellet was reextracted once more in 10 ml 1× binding buffer by douncing, incubated on ice for 30 min, and centrifuged at 30,000g for 30 min, and the supernatant was collected. The 2 supernatants were pooled, filtered, and purified through a 1-ml HiTrap nickel-chelating column (Pharmacia, Piscataway, NJ) or nickel agarose resin (Qiagen, Valencia, CA) equilibrated with 1× binding buffer. HIV-1 IN protein was eluted with increased concentrations of imidazole. The protein concentration was measured by the Bradford method (Bio-Rad, Hercules, CA). The protein was dialyzed against 1 M NaCl, 20 mM N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid, pH. 7.5, 0.1 mM EDTA, 1 mM dithiothreitol and 10% glycerol at 4°C overnight and stored in aliquots at -80°C.
Oligonucleotide substrates
Oligonucleotide sequences corresponding to the U5 terminus of the HIV-1 genome were hybridized to generate a substrate for enzymatic assays (E strand, 3′-TGACGATCTCTAAAAGGTGTA-5′ and A strand, 5′-ACTGCTAGAGATTTTCCACAT-3′). Oligonucleotides were purified on 20% denaturing polyacrylamide gels; the E strand was 5′ end-labeled with γ-32 P ATP (Dupont-NEN, Boston, MA) and T4 DNA kinase as described previously. 17 Synthesis, high performance liquid chromatography (HPLC), and polyacrylamide gel electrophoresis (PAGE) purification of modified oligonucleotides were performed at Integrated DNA Technologies, Inc. (Coralville, IA). Substrates were modified for the microplate assay by the incorporation of BIO at the 5′ end of the E strand, and digoxygenin at the 3′ end of the target DNA strand.
Radioactive integration assays
Standard enzyme reactions for HIV-1 IN were made in a final volume of 15 µl and contained 25 mM PIPES pH 6.8, 10 mM βmercaptoethanol, 5% glycerol, 7.5 mM MnCl 2 , 1 pmol substrate and 50 ng IN as previously described. 17 Reactions were terminated by adding an equal volume of loading dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.5% xylene cyanol). Reaction products were separated on 20% polyacrylamide denaturing gels and subjected to autoradiography.
Microplate assay
The HIV-1 U5 substrate (BIO-HIV-U5) was made by annealing the 5′ BIO-labeled E strand and its complementary A strand in 1× DNA coating buffer (100 mM TRIS-HCl, pH 7.5, 150 mM NaCl and 0.1% Tween 20) . Seventy microliters of 8 pmol/µl of the BIO-HIV-U5 substrate in 1× DNA coating buffer was added to streptavidin-coupled microplate wells, incubated at room temperature for 2 h, and washed 3 times with 200 µl phosphate buffered saline containing 0.1% Tween 20 (PBST) to remove unbound DNA. Wells were blocked with 100 µl of 0.1µg/µl bovine serum albumin and 0.1 µg/µl sonicated salmon sperm DNA for 20 min at room temperature in 1× DNA coating buffer, and washed 3 times with PBST. IN (150 ng in 2 µl) was added and preincubated in the DNA-coated wells for 5 min at room temperature in reaction buffer (25 mM PIPES, pH 6.8, 10 mM BME, 5% glycerol, 0.1 µg/µl BSA, and 3.0 mM MnCl 2 ). Drugs were added either in water or in DMSO to a final concentration of 10% DMSO into the final reaction volume of 40 µl. Three microliters of 40 pmol/µl of the 3′ DIG-labeled E/A target DNA, annealed in water with 200 mM NaCl, was added and incubated at 37°C for 2 h. After incubation, the wells were washed 3 times with PBST, and the DNA was denatured by incubating the wells 3 times with 100 µl of 30 mM NaOH, 200 mM NaCl, and 1 mM EDTA for 5 min at 37°C. The wells were washed again with PBST 3 times and incubated with 100 µl of 200 mU/ml anti-DIG antibody diluted in PBST for 1 h at 37°C. Finally, wells were washed with PBST, and 100 µl of ABTS substrate was added. Plates were read at 405 nm with a Biotek FL600 microplate fluorescent reader (Perkin Elmer, Boston, MA).
RESULTS
Characterization of HIV-1 IN used to develop microplate assays
The first step toward the development of the microplate assay was the purification and characterization of the HIV-1 IN. IN was purified from the soluble fraction using nickel affinity chromatography as described in the materials and methods section. Importantly, only fractions from the purification that contained both 3′ processing and strand transfer activity using the standard radioactive assays for 3′ processing and strand transfer were used in the development of the assay (Figs. 1A and 1B). Fractions with both activities were then titrated to define the concentration for maximal activity. Of importance, the optimal concentration required for IN activity differed with different purifications and fractions and ranged from 76 ng to 350 ng. The IN used in these studies was also characterized to define the optimal pH. Optimal 3′ processing and strand transfer activity was noted at pH 6.8 (Fig. 1C ).
Optimization of the microplate assay
In our microplate assay, the 5′ end of the E strand has a BIO label (BIO-E) and the target DNA has a DIG label on the 3′ end of the E strand (DIG-E) ( Fig. 2A ). Thus, we measure the integration of the BIO-E strand into the target, DIG-E strand ( Fig. 2B ). To optimize the robustness of our assay, we varied the concentrations of metal ion, substrate, target concentration, and protein concentration and defined the range that would give the highest levels of IN activity. The optimum concentration of Mn 2+ required was 3 mM when no EDTA was carried over from the substrate preparation ( Fig. 3A) . But when the EDTA concentration was 1.5 mM (carried over from the substrate preparation), the maximum activity observed shifted to the metal ion concentration of 7-8 mM ( Fig. 3B ). We thereafter excluded EDTA during the preparation of the DNA substrates and used 3 mM Mn 2+ in all subsequent reactions.
The maximum amount of DNA that can be bound by a single streptavidin-coated well is 80 pmol (Manufacturer manual, Roche Applied Science). Titration of target and donor DNA showed 560 pmol as optimal for DNA coating of the well, as determined by the efficiency of the reaction (data not shown). Similarly, we also determined that 150 pmol of the DNA to be added (target or donor) was optimal. The concentration of IN required for a maximal signal was also determined by titration of IN. Similar to what we have observed with the gel assay, the optimal concentration required for IN activity differed with different purifications and fractions and ranged from 76 ng to 350 ng (data not shown). Throughout the experiment shown herein, we used a concentration of 150 ng of IN. later use because we observed that condensation in the plate during storage reduced the signal of the assay.
To further test the robustness of this assay, we explored additional substrates, wash conditions, and denaturation conditions. Of note, we analyzed the addition of a target substrate with 5′ DIG label. In this reaction, 5′ DIG-labeled E substrate (target) was employed with 5′ BIO-labeled E strand (donor) that was coated in the well. Since integration occurs 5′ to 3′, the product of this reaction will not have the DIG label after reaction and subsequent denaturation. The DIG label will remain in the well only if there is nondenatured double-stranded DNA sticking to the coated DNA. A reaction with 5′ DIG-labeled E target and 5′ BIO-labeled E substrate will give insight into the level of nonspecific products. Importantly, no activity was observed with these substrates (data not shown), suggesting a very low background in our assay of nonspecific hybridization. Also of interest, we found that increasing the concentration to 100 mM NaOH in the denaturation buffer did not reduce the background further. We also tested whether changing the wash conditions affected the readout. Both modifications did not further reduce the background.
Finally, we preassembled the target DNA with IN and performed strand transfer by coating BIO-labeled target DNA in the wells. Reactions that had been preincubated with target DNA and IN peaked at 3 mM Mn 2+ . There was little difference in the signal with preincubation of target DNA with IN as compared with preassembly of IN on the donor strand ( Fig. 3C ).
Statistical evaluation of assay performance
The ability to identify active compounds ("hits") from large chemical libraries accurately and rapidly is the ultimate goal in developing effective HTS assays. The ability to identify hits from a particular HTS assay depends largely on the suitability or quality of the assay used in the screening. Recently, a screening window coefficient, called Z factor, has been defined. 18 The Z factor is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements and, therefore, is suitable for assay quality assessment. Analysis of the data resulting from the experiments presented in Figures 3 through 6 and described herein indicates the microplate assay we developed for HIV-1 IN has a Z factor value ranging from 0.7 to 0.85 depending on the assay conditions (Table 1 ). This reflects the robustness of the assay and indicates it is suitable for accurate identification of active "hit" compounds in an HTS format. While screening of drugs, we include 8 replicates of positive and negative controls each time in a 96-well microplate to validate the assay using the Z factor statistics.
Target DNA selection
Because our assay distinguishes the target and donor DNA strands in the reaction, we asked which of the 2 strands (E or A) was preferred as the target in the reaction. To test for this preference, we used a 5′ BIO-labeled E donor DNA (5′ BIO E) and 3′ DIG-labeled target DNA (E and A strands 3′ DIG-labeled separately with the complementary strands, 3′ DIG EA or 3′ DIG AE, respectively). Because strand transfer follows 5′-3′ direction, the 5′ BIO EA acts as the donor DNA and the 3′ DIG EA or the 3′ AE acts as the target DNA in this reaction. Because only the strand transfer products remain in the well after the denaturation step, it is convenient to measure the difference in activity with both the strands for targeting. Within our assay conditions, we titrated for metal concentration from 1 mM to 7 mM for both the target strands. The optical density value peaked at a Mn 2+ concentration of 3 mM with E strand as the target (Fig. 4A) . In contrast, when the A strand was used as a target, there was very weak intensity of signal as compared with when the E strand was targeted. In addition, the optical density value peaked at 5 mM Mn 2+ (Fig. 4B ). This finding sug- gests a preference for E strand as target DNA in comparison with the A strand.
Reverse transcriptase inhibits integration
It has been previously shown that reverse transcriptase (RT) inhibits the strand-transfer reaction at a molar ratio of 2:1 (RT to IN). 19, 20 In contrast, Hehl et al. have shown that with different assay and buffer conditions, RT at different molar ratios enhances strand transfer. 21 As a result, we were interested in how RT behaved in our HITS™ assay. Again in these studies, the substrate with BIO la- beled on the 5′ end of the E strand was used as the donor and the DIG labeled at the 3′ end was used as target in the reaction. We used 1:1 molar ratio of RT to IN in all our experiments to study the effect of RT on strand transfer. First, we addressed whether RT competed with IN for substrate or target DNA. We preincubated IN and RT with substrate DNA or target DNA, on ice. After 10 min, we added the remaining factors as described in the materials and methods section for the assay and incubated for an additional 2 h at 37°C. In each reaction, the strand transfer reaction was inhibited to the level of control with no metal (Fig. 5A ). A similar result was observed when we assayed for order of addition, using the standard radioactive assay (Fig. 5B) . The control reaction with RT and DNA substrates alone had no activity. This result agrees with the previously published data. 19, 20 Since the activity of IN might be different at physiological temperature, we checked the effect of preincubation of the reaction at 37°C, using the microplate assay. In contrast to what we observed with preincubation of IN with DNA at 4°C, RT did not block integration when IN was preincubated with DNA at 37°C for 5 min. In contrast, when RT was preincubated with the DNA substrates for 5 min and then with the addition of IN and further incubated at 37°C for 2 h, RT inhibited strand transfer activity in the microplate assay (Fig. 5C ). We also obtained identical results with identical order of addition experiments that were analyzed with radioactive gelbased assay. In fact, even when IN was preincubated with the DNA for 1 min at 37°C followed by the addition of RT, we did not observe inhibition of the strand transfer (Fig. 5D) . A control reaction with IN alone after 1 min of incubation at 37°C was made for comparison. No strand transfer products were observed (Fig. 5D ). Strand transfer products were detected after 7 min, which showed the reaction was incomplete during the preincubation period under these assay conditions.
Screening nucleoside analogs for inhibitors
Finally, we explored the HITS™ assay in a screen of nucleoside analogs (Southern Research Institute [SRI] library, Birmingham, AL). We screened a small library at a concentration of 25 µM in duplicate. Surprisingly, some nucleoside analogs slightly enhanced the strand transfer activity (Fig. 6 ). Compounds showing more than 80% inhibition were analyzed further in both gel-based and microplate assays. To find out the IC 50 of the compound, we further tested the activity at different lower concentrations below 25 µM using serial 1:2 or 1:5 dilutions. We used the Merck (Whitehouse Station, NJ) compound L-708906 as a control, and its IC 50 was 616 nM.
DISCUSSION AND CONCLUSION
The absolute requirement for IN in the life cycle of HIV-1 and the absence of a counterpart in human cells makes it an attractive target for antiviral chemotherapeutic intervention. Although there are currently no Food and Drug Administration-approved antiviral drugs that target HIV-1 IN, many laboratories are active in the pursuit of clinically useful IN inhibitors. 13, 22 Compounds that inhibit HIV replication in cell culture by targeting IN have been identified. 12, 14 Polyhydroxylated aromatic compounds are 1 class of molecules that have been identified as IN inhibitors. 23, 24 Molecular modeling techniques have generated pharmacophores from a series of active compounds against IN and in hopes of identifying additional classes of inhibitors. [25] [26] [27] Many compounds have been designed and synthesized to establish structure-activity relationships of compounds identified as IN inhibitors. [28] [29] [30] [31] Chemically modified inhibitors as photo affinity probes have been utilized to identify a unique binding site on IN that is responsible for the inhibitory mechanism of nucleotides 32 such as dideoxyuridine and 3′ azidothymine (AZT) monophosphates. 33 During the past decade, several rapid microplate assays have been developed to measure the enzyme activity of the HIV-1 IN that can be used to screen for antiviral drugs in vitro 11, 15, 16 These assays measure 3′ processing and strand transfer activity together or measure strand transfer activity alone, and hence offer a viable approach to the screening of antiviral compounds. The HITS™ assay described herein can be employed to measure 3′ processing and strand transfer or strand transfer alone. We have worked to capitalize on the strengths reported for the microplate assays described to date in development of our assay. 11, 15, 16 In addition to HTS, 2 notable improvements have been made in this assay. First, the entire assay can be conducted in the context of a single microplate. Second, we optimized the assay to reduce nonspecific binding of IN and nonspecific hybridization of the target strand. It is highly conceivable that the compounds previously identified as hits were those that affected the complex formation and not catalysis itself. The possibility of nonspecific hybridization with the complementary strands was avoided through the denaturation step. Hazuda et al. demonstrated a similar assay, 15 with reactions done in situ without a denaturation step. However, in their assay, they used a heterologous DNA strand as the target DNA. Because the viral sequence in this case is different from that of the viral DNA end, complex formation could be minimized. We observed high back- Figure 3B 0.6618 3. Figure 3C 0.612 4. Figure 4A 0.596 5. Figure 4B 0.489 6. Figure 5A 0.85 7. Figure 5C 0.5081 8. Figure 6 0.4716
The Z factors were calculated using 8 replicates of positive-control and 8 replicates of negative-control reactions in each plate, using the formula described by Zhang et al. 18 In the experiments in which optimization is involved (Figs. 3A, 3B, 3C , 4A, and 4B) the Z factors were calculated using the highest value as positive control and the nonmetal reaction as negative control. ground in the control reaction when conducted without a denaturation step. The background was most likely the result of a strong complex formed between the donor DNA, target DNA, and IN. One of the major advantages of this assay over the assay described by Hazuda et al. 15 is that it has minimized the background by introducing a denaturation step. In effect, this step ensures that nonspecific binding of the complementary strand is reduced as well as nonspecific complexes of IN with DNA. Moreover, our assay has the ability for order of addition studies for mechanism of inhibitor action with substrate configuration. In the assay described by Hwang et al., 16 a denaturation step was included to minimize the background. But their assay was performed in reaction tubes and was captured to microplate after reaction. In contrast, the HITS™ assay avoids the inconvenience of performing the reaction separately in the tubes and transferring to microplate afterward. In the absence of IN or metal ion, there was very little signal observed in our assay.
The IC 50 reported for L-708906 compound by Hazuda et al. is 100 nM for strand transfer using their microplate assay. 12 Although not measurably different, the higher IC 50 observed for the same compound in our assay may be because our assay measures all the reactions together, DNA-integrase complex formation, 3′ processing and strand transfer. Moreover, the IC 50 for 3′ processing by L-708906 has been shown to be always higher in other assays. 34 The DNA strand, which is selectively targeted for strand transfer by IN, has not been previously reported. Because the strand transfer reaction occurs only in the 5′ to 3′ direction, we could easily distinguish between the donor and target DNA. The reason for the selectivity of E strand compared with A strand as target DNA is intriguing. The E strand has 4 adjacent adenosines compared with the 4 adjacent thymidines in the A strand. It is possible that IN has a preference for A-rich regions. Also it has been shown previously that IN prefer positions with maximal distortion in the target DNA for integration. 35, 36 Because the AT-rich regions are more prone to melting and thus distortions, these regions could be a favored place for strand transfer. 37 From our studies, we hypothesize that IN preferred AT regions and integrated after or before adenosines. But further studies are required to substantiate this hypothesis.
Previous reports concerning the role of RT in the integration reaction have reported both enhancement as well as inhibition of HIV-1 IN. Both Tasara et al. and Oz et al. used radiolabeled oligonucleotide substrates to measure strand transfer activity. 19, 20 In the HITS™ assay, as well as the gel-based assay, a similar inhibition of strand transfer was observed. In contrast to what these authors saw with preincubation at 4°C, we observed no inhibition when IN was preincubated at 37°C. This observation suggests that IN at a physiologically relevant biological temperature may differ in its ability to interact with the substrate DNA or its other protein partners. Taken together, this information suggests that the inhibition of integration by RT is by the competitive binding of RT with the DNA and no direct inhibition of IN by RT can be suggested with the data we observed here. In contrast, Erik et al. used supercoiled plasmid DNA as target DNA to measure the strand transfer reaction with labeled oligonucleotide and observed enhancement of strand transfer in the presence of RT. 21 Using oligonucleotide substrates alone, they also observed inhibition of 3′ processing as reported by Tasara et al. and Oz et al. These observations taken together suggest that the reported differences in IN activity were because of different assay conditions. Our preincubation study results show that while studying the mechanism of inhibition of any novel drug, IN has to be preincubated with the drug or substrate at biological temperature rather than at 4°C to best mimic the biological system.
In summary, the HTS technology described herein for HIV-1 IN is suitable for rapid, efficient screening of drug candidates as well as molecular probes for mechanistic studies. Future efforts will aim toward using the HITS™ assay to identify new molecular scaffolds that might be explored and developed as effective antiviral drugs for treatment of AIDS. Furthermore, it is hoped that this technology will be used to explore the interactions of other viral and cellular proteins in the enzyme reaction.
